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ABSTRACT 
 
Neuroinflammation ​in utero may result in lifelong neurological disabilities. Astrocytes play a            
pivotal role, but the mechanisms are poorly understood. No early postnatal treatment strategies             
exist to enhance neuroprotective potential of astrocytes. We hypothesized that agonism on α7             
nicotinic acetylcholine receptor (α7nAChR) in fetal astrocytes will augment their neuroprotective           
transcriptome profile, while the antagonistic stimulation of α7nAChR will achieve the opposite.            
Using an ​in vivo - ​in vitro model of developmental programming of neuroinflammation induced              
by lipopolysaccharide (LPS), we validated this hypothesis in primary fetal sheep astrocytes            
cultures re-exposed to LPS in the presence of a selective α7nAChR agonist or antagonist. Our               
RNAseq findings show that a pro-inflammatory astrocyte transcriptome phenotype acquired ​in           
vitro by LPS stimulation is reversed with α7nAChR agonistic stimulation. Conversely,           
antagonistic α7nAChR stimulation potentiates the pro-inflammatory astrocytic transcriptome        
phenotype. Furthermore, we conduct a secondary transcriptome analysis against the identical           
α7nAChR experiments in fetal sheep primary microglia cultures and discuss the implications for             
fetal and postnatal brain development. 
 
  
2 
Introduction 
Glial cells (astrocytes and microglia) play a role in neuroinflammation and both cell types              
acquire a specific reactive phenotype when stimulated by lipopolysaccharide (LPS).​(1)          
Activation of glial cells may lead to neuronal cell death. Activation of nicotinic α7 receptors               
(α7nAChR) suppresses the LPS-induced reactive phenotype of microglia and astrocytes and           
thus counteracts the deleterious effect regarding neuronal viability.​(2–8)  
In the periphery the efferent fibers of the Vagus nerve activate α7nAChR on effector              
cells and inhibit inflammation.​(9) In the brain, fibers arising from the Nucleus tractus solitarii              
spread into both hemispheres and their activation may lead to a widespread central             
anti-inflammatory effect.​(10,11)​(5) It is currently insufficiently tested if this is also true for the              
fetal brain.  
In a previous experiment we investigated the effect of α7nAChR stimulation on            
LPS-induced microglia-activation in a double hit model of sheep fetal microglia. In the current              
experiment, we extended this investigation to study the role of α7nAChR in fetal sheep              
astrocytes. These experiments may help to shed light on neurodevelopmental disorders such as             
autism spectrum disorder (ASD) or schizophrenia, that are thought to involve neuroinflammation            
during the fetal period.​(12,13)  
We hypothesized that (1) under exposure to LPS, α7nAChR agonist stimulation in fetal             
astrocytes augments their neuroprotective profile, while the antagonistic stimulation reduces it;           
(2) a LPS double-hit (first ​in vivo ​, then ​in vitro ​) on astrocytes exacerbates these effects similar to                 
microglia as demonstrated before. Using an ​in vivo ​- ​in vitro fetal sheep model ​(14)​, we validate                 
these hypotheses via RNASeq analysis in primary fetal astrocyte cultures exposed to LPS in the               
presence of a selective α7nAChR agonist or antagonist. We compare these findings to the              
previously published results in identically conducted microglia experiments.​(3,15)  
 
 
 
 
 
 
  
3 
Methods 
 
Study approval 
This study was carried out in strict accordance with the recommendations in the Guide              
for the Care and Use of Laboratory Animals of the National Institutes of Health. The respective                
in vivo and ​in vitro protocols were approved by the Committee on the Ethics of Animal                
Experiments of the Université de Montréal (Permit Number: 10-Rech-1560). 
 
Astrocytes isolation and purification  
The detailed protocol has been presented elsewhere.​(3) Briefly, fetal sheep brain tissues            
were obtained during sheep necropsy after completion of the ​in vivo experiment to conduct the               
in vitro study (Fig. 1). In the ​in vivo experiments, three ​in utero instrumented fetal sheep were                 
treated intravenously with LPS (400ng/fetus/day) derived from E. coli (Sigma Cat. no L5293, E.              
coli O111:B4, ready-made stock solution at a concentration of 1mg/ml) on experimental days 1              
and 2 at 10:00am to mimic high levels of endotoxin in fetal circulation (so-called first LPS                
exposure or first hit). Three ​in utero instrumented fetal sheep were used as control receiving               
sterile saline. The instrumented fetuses were referred to as primary fetuses. In case of twins,               
twin fetuses were not instrumented and their brains directly used for subsequent cell culture.              
Fetuses not exposed to LPS, either primary or twins, were designated “naïve” (no LPS exposure               
in vivo ​). Instrumented animals that received LPS ​in vivo were used for second hit LPS exposure                
in vitro ​. 
Astrocytes are the major adherent cell population in flask. Astrocytes were purified by             
passage into a new T75 flask for 4-5 times before any manipulations and treatments. After               
floating microglia collection, the adherent cells were detached by trypsinization (Trypsine 0.25%            
+ EDTA 0.1%, Wisent Cat. No 325-043-EL) and re-plated into a new flask. Cells were cultured                
for another 7 days with 10% ready-to-use medium (DMEM plus 1% penicillin/ streptomycin, 1%              
glutamine, in addition with 10% heat-inactivated fetal bovine serum (Gibco, Canada Origin)).            
The cell passage procedure took 4-5 weeks until purified astrocytes could be used for the ​in                
vitro ​ experiment. The cell culture conditions were 37°C, 5% CO​2​. 
Pure astrocytes were plated into a 24-well plate at 1 x 10​5 cells/mL with 10% DMEM for                 
another 7 days, and then treated with LPS or saline for 6h.  
Cell-conditioned media were collected for cytokine analysis. To verify astrocytes purity, a            
portion of cells was plated into Lab-Tek 8 well chamber glass slide (Thermo Scientific) for               
immunocytochemistry (ICC) analysis. Glial fibrillary acidic protein (GFAP) was used as an            
astrocyte marker; cells were counterstained with Hoechst.​(15) 
 
Astrocyte cell culture and treatment 
Prior to exposure to LPS (Sigma Cat. no L5024, E. coli O127:B8) at a concentration of                
100 ng/ul, cells were pretreated for 1 hour with either 10nM AR-R17779 hydrochloride (Tocris              
Bioscience Cat# 3964), a selective α7nAChR agonist, or 100 nM α-Bungarotoxin (Tocris            
Bioscience Cat# 2133), a selective α7nAChR antagonist. Optimal dose of AR-R17779 (A) or             
α-Bungarotoxin (B) was chosen based on a dose-response experiment with LPS. We have             
tested 0, 10, 100, and 1000nM of α-Bungarotoxin and 0, 1, 10, and 100nM of AR-R17779 in the                  
4 
absence or presence of 100ng/ul LPS, and measured IL-1β concentrations in cultured media as              
the endpoint. The 100nM α-Bungarotoxin and 10nM AR-R17779 were chosen because the cells             
responded in a linear range as indicated by IL-1β production.  
AR-R17779 was reconstituted in DMSO as stock solution, serial dilutions were made to             
prepare the working stock; to obtain 10nM AR-R17779 in concentration per well, 5ul working              
stock was added well by well containing 500ul media; only DMSO was added in control well,                
therefore, the DMSO concentration per well was 1%. α-Bungarotoxin was reconstituted with            
culture media into a stock solution and underwent serial dilutions.  
In a complete cell culture experiment, we had four experimental groups: Control (naïve             
control), LPS100 (naïve LPS), LPS100+B10 (naïve LPS+B) and LPS100+A10 (naïve LPS+A).           
Second hit cell cultures were designed with the same pattern and divided into four experimental               
groups: Control (SHC), LPS100, LPS100+B100 and LPS100+A10.  
 
Measurement of the cytokine IL-1β in cell culture media  
The approach is described elsewhere.​(14,16) Briefly, IL-1β concentrations in cell culture           
media was determined by using an ovine-specific sandwich ELISA. 96-well plates were           
pre-coated with the mouse anti sheep monoclonal antibodies (IL-1β, MCA1658, Bio Rad AbD             
Serotec) at a concentration of 4µg/ml on an ELISA plate at 4°C overnight. After 3 times wash                 
with washing buffer (0.05% Tween 20 in PBS, PBST), plates were blocked for 1h with 1% BSA                 
in PBST for plasma samples or 10% FBS for cell culture media. Recombinant sheep proteins               
(IL-1β, Protein Express Cat. no 968-405) were used as ELISA standard. All standards and              
samples were run in duplicate (50µl per well). Rabbit anti-sheep polyclonal antibodies (IL-1β,             
AHP423, Bio Rad AbD Serotec) at a concentration of 4µg/ml were applied in wells and               
incubated for 30 min at room temperature. Plates were washed with washing buffer for 5-7               
times between each step. Detection was accomplished by assessing the conjugated enzyme            
activity (goat anti-rabbit IgG-HRP, dilution 1:5000, Jackson ImmunoResearch, Cat. No          
111-035-144) via incubation with TMB substrate solution (BD OptEIA TMB substrate Reagent            
Set, BD Biosciences Cat. No 555214); colour development reaction was stopped with 2N             
sulphuric acid. Plates were read on an ELISA plate reader at 450 nm, with 570 nm wavelength                 
correction (EnVision 2104 Multilabel Reader, Perkin Elmer). The sensitivity of IL-1β ELISA was             
41.3 pg/ml. The intra-assay and inter-assay coefficients of variance were <5% and <10%,             
respectively. 
 
RNAseq approach 
Nine replicates of astrocyte culture were studi ​ed, with one control and three treatment             
groups (Ctrl, LPS100, LPS+A10, LPS+B100) per replicate. Four replicates were used for            
RNAseq based on the RNA quality, of which 3 replicates of naive, one replicate of second-hit,                
with one treatment missing in this second-hit replicate (agonist treatment), fifteen samples in             
total were assessed with RNAseq in this study (Table 1).  
 
RNA extraction and quantification ​: We used Qiagen RNeasy Mini Kit (Cat no 74104) for RNA               
extraction. RNA quantity and quality (RNA integrity number, RIN) was established by using a              
RNA Nano Chip (Agilent RNA 6000 Nano Chips) with Agilent 2100 BioAnalyzer. All samples              
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had an acceptable RIN value ranging from ​8.4 to 9.6 ​. A total of twelve naïve astrocyte cultures                 
from four sets of replicates was selected for RNA sequencing at high throughput, as well as                
three second hit astrocyte cultures(Table 1).  
RNA-seq libraries were prepared using the TruSeq stranded mRNA kit (Illumina cat            
#20020594) and quality control was performed on the Agilent TapeStation and using the KAPA              
SYBRFAST qPCR kit. Single read 100-bp sequencing was performed in rapid mode on a              
HiSeq 2500 at the University of Washington Northwest Clinical Genomics Lab (Department of             
Pathology). 
 
RNAseq data analyses 
 
Astrocytes 
The goal for this analysis was to compare the single hit LPS treated samples to Control,                
as well as making comparisons between the LPS treated samples (e.g., testing for changes due               
to the additional agonist or antagonist pre-treatment). The second hit samples had no replicates,              
so we could only make the directed comparisons between the single and second hit samples.               
For example, comparing the single and second hit LPS treated samples, as before.​(3) 
We aligned the reads to the Oar_v3.1 transcriptome using the salmon aligner ​(17)​, which             
infers the most likely transcript for each read using a quasi-mapping algorithm. We then              
‘collapsed’ the transcript read counts to the gene level by summing up the reads for each gene’s                 
transcripts, using the Bioconductor tximport package.​(18) In the end, we had a set of read               
counts per gene, for each sample. 
Four replicates were used for RNAseq, with one control and three treatment groups Ctrl,              
LPS, LPS+A10, LPS+B100) per replicate. There were 3 replicates of naïve, one replicate of              
second-hit, with one treatment missing in this second-hit replicate (second-hit + agonist, SHA),             
fifteen samples in total were assessed with RNAseq in this study (Table 1). The instrumented               
fetuses were designated as primary fetus, identified as animal ID+P (stands for primary),             
whereas animal ID+T stands for non-instrumented twins. 
To compare astrocytes transcriptomes, we used the Bioconductor edgeR package ​(19)​,          
to fit a generalized linear model with a negative binomial link function, and made comparisons               
between groups using quasi-likelihood F-tests. 
We fitted the model described above, including the treatment effect for each animal, and              
made the comparisons, incorporating ​a fold change criterion into the test. In other words, the               
conventional test for a difference is between the null hypothesis H​0 ​: β = 0 versus the alternative                  
hypothesis H​A ​: β ≠ 0, but this may include very small changes that are likely to be biologically                   
meaningless. One alternative to exclude such genes is to use a ​post hoc fold change               
adjustment, where we select genes based on the observed fold change between groups. This is               
problematic because we ignore the imprecision in our estimate of fold change. A better method               
is to incorporate the fold change into our inference, where we test H​0 ​: β < |c| against the                   
alternative H​A ​: β ≥ |c|, for some constant fold change. By doing this, we are testing to see if we                     
have evidence that the underlying population differences are larger than a given fold change,              
rather than simply testing that our sample data fulfill those criteria. ​We used a 1.5-fold change,                 
and a false discovery rate (FDR) of 0.05 as criteria to define significantly differentially expressed               
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genes, ​meaning that we expect that there are, at most, 5% false positives in our set of                 
significant genes.  
 
Microglia - astrocytes transcriptome comparisons 
We also made comparisons to the existing RNAseq data that our lab generated using              
primary cultures of fetal sheep microglia from the identical experimental design in three             
biological replicates. This data has been published and the data set is accessible online.​(14) 
We downloaded the FASTQ data from SRA and processed using the same            
salmon/tximport pipeline we used for the astrocyte samples. The only difference was in the              
modeling step, where we converted the count data to log counts/million and estimated             
observation-level weights using the limma voom function. We also computed sample-specific           
weights that are intended to down-weight any samples that are not very similar to other samples                
of the same type. We then fit a conventional weighted linear model and made empirical Bayes                
adjusted contrasts between various groups. By incorporating sample-specific weights we were           
able to account for a single sample (LPS100 treated animal 4414T), which had significantly              
fewer reads, perhaps due to some technical problems. 
 
Venn diagrams 
We sought to learn which genes are unique to a given comparison, and which are               
shared between two or more of those comparisons. Thus, we generated Venn diagrams for              
three sets of comparisons. We made a Venn diagram for the three comparisons of treated vs.                
control, a two-way Venn diagram of the agonist + LPS versus either LPS alone or LPS plus                 
antagonist (this shows that there is very little difference between LPS and LPS plus antagonist),               
and finally we made a Venn diagram of the one-hit versus two-hit for all three treatments. The                 
genes in any intersection between comparisons had to be significantly differentially expressed in             
both (or all three, depending on the intersection) of the comparisons. In addition, the direction of                
change had to be the same as well. For example, if a given gene was differentially expressed in                  
LPS100 vs control and LPS100+A10 vs control, and it is either up or down-regulated in both                
comparisons as well, then it was listed in the intersection between those two comparisons. If it                
was significant in both comparisons, but was up-regulated in one comparison, but            
down-regulated in the other, then it was listed in the unique portion of the Venn diagram for                 
each comparison.  
 
Statistical analyses and data repository 
Generalized estimating equations (GEE) modeling approach was used to assess the           
effects of LPS and drug treatments on IL-1β. We used a linear scale response model with                
LPS/drug treatment group (main term “treatment”) and presence or absence of second hit             
exposure (main term “hit”) as predicting factors to assess their interactions using maximum             
likelihood estimate and Type III analysis with Wald Chi-square statistic. SPSS Version 25 was              
used for these analyses (IBM SPSS Statistics, IBM Corporation, Armonk, NY). Significance was             
assumed for p < 0.05. Results are provided as median {25-75} percentiles. Not all              
measurements were obtained for each animal studied, as indicated.  
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Ingenuity Pathway Analysis (IPA, Qiagen, 2019) was used for identification of signaling            
pathways unique to each treatment. 
The raw RNAseq data has been deposited under GEO accession number ​GSE123713 ​.            
The analytical pipeline to allow reproduction of this analysis, in the form of an Rmarkdown               
document, will be made available upon request. Statistics from all comparisons (t-statistics, log             
fold changes, FDR values, dynamically linked Venn diagrams) can be found in supplemental             
document under the ​DOI ​10.5281/zenodo.2609202 ​.  
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Results and Discussion 
 
Cytokine secretion profile 
The absolute values of IL-1β produced by naive (first hit) and second hit astrocytes at               
baseline, under LPS exposure and with preceding agonist or antagonist incubation are            
presented in Table 2. As reported, LPS treatment induced IL-1β increase in astrocytes.​(14)             
There was no difference in first and second hit astrocytes at baseline or when exposed to LPS                 
alone. Our focus here was on the effect of α7nAChR modulation on LPS-triggered IL-1β              
production. Consequently, we expressed the data as fold-changes compared to sham treatment            
(LPS, Fig. 2, LEFT). We present the response of primary microglia cultures side-by-side (Fig. 2,               
RIGHT) in form of re-analysis of previously published data.​(3)  
For astrocytes, the main terms “hit” and “treatment” as well as their interaction were              
significant (all p<0.001). Agonistic stimulation of the α7nAChR appeared, surprisingly, to result            
in a relative increase of IL-1β concentration, further potentiated in second hit astrocytes. This              
effect was absent in first hit astrocytes cultures treated with the α7nAChR antagonist and less               
pronounced but present in the second hit cultures.  
For microglia, the main terms “hit” and “treatment” were not significant (p=0.716 and             
p=0.666, respectively), but their interaction was significant (p=0.026, cf. Fig. 1 in ​(3)​).  
The overall pattern of IL-1β levels in response to LPS exposure with prior α7nAChR              
stimulation was inverted in astrocytes compared to microglia. In astrocytes, both first hit and              
second hit cell cultures responded under antagonistic stimulation of α7nAChR with relative            
decrease of IL-1β production. In microglia, in contrast, first hit (naive) cultures behaved             
intuitively under the same conditions, showing a rise in IL-1β production. However, second hit              
microglia cultures, similar to second hit astrocytes, showed a drop in IL-1β production with              
α7nAChR antagonistic stimulation. In contrast again, agonistic α7nAChR stimulation in both           
second hit glia cultures resulted in higher than first hit IL-1β production, albeit, the magnitude of                
this rise was ~3.5-fold larger in astrocytes suggesting differences in sensitization of these glia              
cells to previous LPS exposure ​in utero​. These counter-intuitive findings of α7nAChR stimulation             
in astrocytes on the individual IL-1β secretion stand in contrast to the transcriptome-level             
findings we discuss below. We attempt to tie together these results in the general discussion               
section. 
 
Whole transcriptome analysis 
Mapped reads aligned to any transcript from the Oar_v3.1 transcriptome at 66% which is              
good. Principal component analysis (PCA) showed large differences between the different           
treatment groups, and much smaller differences within each group, indicating that we have a              
good signal with likely many differentially expressed genes (DEG) to be found (Fig. 3).  
We present in Table 3 the number of genes for each comparison as well as the top ten                  
signaling pathways IPA identified. The results of the analysis on the entire data set are also                
accessible with search function via ​this​ repository. 
PCA showed two transcriptome clusters (Fig. 3): control, LPS single-hit and second-hit            
astrocytes pre-treated with α7nAChR agonist and LPS single-hit and second-hit astrocytes           
pre-treated with α7nAChR antagonist. That is, a pro-inflammatory transcriptome astrocyte          
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phenotype acquired in vivo or ​in vitro by LPS stimulation is reversed with α7nAChR agonistic               
stimulation. Conversely, antagonistic α7nAChR stimulation potentiates the pro-inflammatory        
astrocytic phenotype. The PCA level observations are substantiated further by the IPA analysis             
of key signaling pathways presented in Table 3. The visualization of the up or down regulation                
of the implicated pathways can be accessed on ​GitHub in its entirety. Here we focus on some                 
key findings in top ten signaling pathways. LPS treatment triggered activation of            
pro-inflammatory signaling pathways NF-κB and neuroinflammation. Compared to LPS         
exposure alone, pretreatment with α7nAChR agonist reversed both signaling pathways          
activation. Conversely, pretreatment with α7nAChR antagonist up regulated these         
pro-inflammatory pathways. Albeit the pattern overall was similar to the effect of LPS alone,              
activation of these signaling pathways under α7nAChR blockade stood out: Toll-like receptor            
signaling and PI3K signaling. Direct comparison of α7nAChR agonistic and antagonistic           
stimulation yielded reduced activity of NF-κB and STAT3 pathways due to activation of             
α7nAChR, consistent with the expected intracellular anti-inflammatory effect of α7nAChR          
agonism. Another notable pathway activated in α7nAChR agonistically treated astrocytes was           
the Sirtuin signaling. Activation of this pathway in neurons and astrocytes has been implicated in               
AMPK-dependent neuroprotection from ischemic stroke.​(20,21) Adenosine monophosphate       
kinase (AMPK) is a rapid key regulator of neuronal energy homeostasis implicated in fetal              
neuroinflammation.​(22) 
The second half of Table 3 documents some effects of astrocytes memory of LPS              
exposure ​in vivo when re-exposed ​in vitro (second hit effect). Notably, we found a perturbation               
of the iron homeostasis signaling pathway in second hit LPS treated astrocytes which persisted              
under pre-treatment with α7nAChR antagonist, but was reversed with α7nAChR agonist. Similar            
to our finding of second hit signature in microglia, here we ​observed hemoxygenase (HMOX)1              
gene down regulation in second hit astrocytes compared to first hit cultures.​(3,15) HMOX1 is a               
key gene of iron homeostasis. We observed a similar phenomenon in second hit fetal microglia               
compared to single hit microglia.​(15)  
Together, observations on Sirtuin and iron homeostasis signaling reinforce the          
previously reported dual role of energy metabolism in determining inflammatory phenotype in            
glia cells.​(3,15) 
Based on the IPA analysis within the ​Venn diagrams​, the top down-regulated signaling             
pathway unique to LPS treatment was Ephrin A signaling (log(p-value) 3.21, Table 5). Analysis              
of genes unique to α7nAChR agonist treatment showed a reduction of this down-regulation             
(log(p-value)1.58, Table 5). Analysis of genes unique to α7nAChR antagonist treatment had no             
significant effect on this signaling pathway (Table 5). Ephrin signalling has been implicated in              
neuroprotective astrocyte phenotype.​(23) Our findings suggest a neuroprotective effect of          
α7nAChR agonism on ephrin signaling pathway.  
Consistent with the notion of cholinergic signaling involved in stress axis regulation ​(3)​,             
POMC was the second (by IPA ranking) highest up-regulated gene under cholinergic agonist             
treatment, with a log ratio of 3.388 (Cf. ​GitHub repository​).  
 
Comparison to fetal sheep microglial transcriptome 
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PCA in Fig. 4 (top) shows that the main differences between astrocytes and microglia              
RNAseq data are captured on the first two principal components, so a 2D plot may be more                 
useful (Fig. 4, bottom). The intra-group variability is smaller for the astrocytes compared to the               
microglia. This may have to do with the total library sizes: there were several microglia samples                
with very few reads that aligned to any known transcript. 
We compared the IPA-identified top signaling pathways in microglia and astrocytes           
under the LPS and ​α7nAChR signaling manipulation. Table 5 presents the number of genes for               
each comparison and the corresponding findings of the IPA signaling pathway analysis. Overall,             
the response patterns to LPS and modulation of ​α7nAChR signaling were similar between the              
two glia cell types. The signaling pathways common to both astrocytes and microglia are bolded               
in Tables 3 and 4. Intuitively, common pathways activated due to LPS included             
neuroinflammation signaling and NF-κB signaling in some, but not all comparisons. However,            
overall, the overlap on the level of signaling pathway was rather minimal which may explain the                
strong separation by cell type on PCA. It is remarkable that astrocytes, not microglia - the                
primary immune cells of the brain, were characterized by unique inhibition patterns of STAT3              
pathway due to agonistic stimulation of α7nAChR prior to LPS exposure. 
The presented astrocytes - microglia comparison has limitations. The differences          
between the two cell types may be exaggerated by the inevitable technical differences (e.g.,              
reagents). However, all these experiments were run from the same cohort, same animals (in              
some cases), at adjacent times and by the same people. 
 
Do fetal neuroinflammation and stress mediate an increased risk for autism spectrum disorder? 
LPS effects on key genes involved in stress axis activity raised the question about the               
poorly understood role of astrocytes in the signaling pathways of neuroinflammation and            
prenatal stress (PS).​(24)  
Indeed, PS is accompanied by inflammation in the mother and offspring.​(24–28) ​(29)            
Both, PS and fetal neuroinflammation have been implicated in the etiology of ASD.​(30,31) PS              
increases expression of glutamate (Glu) transporter vGluT1 (SLC17A7) resulting in higher levels            
of GLT1.​(32,33)​ ​(33) 
Here, we sought to verify if the exposure of fetal astrocytes to LPS induces upregulation               
of Glu transporters in glia akin to PS.​(32,33)  
Given the known relationship between PS and VGLUT1 expression, we used IPA to             
annotate VGLUT1 gene network with our findings to test for evidence that the network is being                
perturbed by LPS treatment. Across all treatment comparisons, two DEGs were identified in             
astrocytes (common to all comparisons): JAK2 (2.732 (log ratio) upregulated, FDR 3.91E-05)            
and SLC1A2 (2.350 upregulated, FDR 1.80E-04). JAK1 signaling is involved in glucocorticoid            
receptor signaling ​(34) and JAK1/2 signaling is involved in iron homeostasis signaling           
pathways​(35)​, whereas JAK/Stat is involved in IL-6 signaling pathways. SLC1A2 is also known             
as GLT-1 or glial high affinity glutamate transporter; it is implicated in glutamate receptor              
signaling and neuroinflammation signaling pathways.​(36) Upregulation of glial GLT-1 in the           
hippocampus has been reported after chronic stress due to its control by            
glucocorticoids.​(37–39) 
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Again assessing the present findings together with the previously published RNAseq           
data from the identical experiment in ovine fetal microglia ​(3)​, we found GLT-1 to be upregulated                
in microglia and astrocytes regardless cholinergic manipulation (for details see ​GitHub           
repository​). Albeit both pure primary cultures were exposed to LPS, we found the up regulation               
of JAK2 to be unique to astrocytes. This finding is conceptually in line with studies reporting                
brain cell-specific signalling pathways behavior in response to IL-1β.​(40) Much remains to be             
learned about the differences between second messenger signaling cascades involved in           
astrocytes, microglia and neurons in the developing fetal brain exposed to inflammatory stimuli.             
Furthermore, there is still a paucity of data about differences across the species for these               
signaling pathways. 
 
General discussion 
Fetal sheep is the classic model of fetal physiology and neuroscience.​(41) It has been              
used successfully for both integrative physiological as well as genomic studies. In the present              
study, we expand the recently published series of experiments in the same animal model using               
primary microglia cultures to now include primary astrocytes cultures.​(3,14–16) 
Acetylcholine is synthesized by cultured microglia and astrocyte in mouse and rat            
(42,43)​, however, there is no information from other species. It is plausible that the fetal sheep                
brain astrocytes in culture produce acetylcholine, because they appear to respond to α7nAChR             
stimulation. However, we do not know how much acetylcholine is produced, and whether or not               
the speculated endogenous acetylcholine can activate the α7nAChR. This remains worthwhile           
to investigate in future studies.  
The antagonist drug for α7nAChR we used, α-bungarotoxin, is a selective inhibitor for α7              
receptors acting by preventing the opening of nicotinic receptor-associated ion channels (Tocris            
α-bungarotoxin datasheet). By using optimized dose, we treated our astrocyte cells with            
α-bungarotoxin one hour prior to LPS exposure, which would block LPS-induced cytokine            
production in the cells.  
LPS exposure had the anticipated effect of increasing IL-1β production in astrocytes and             
we observed this consistently on the transcriptome level. However, our findings on protein level              
following pre-incubation with α7nAChR antagonist or agonist do not align with those on the              
transcriptome level: present results on protein level do not show a clear hypothesized effect of               
α7nAChR agonism or antagonism on LPS secretion in ovine fetal astrocytes. Such discordant             
behavior on protein and transcriptome levels has been reported and studied systematically to             
represent the rule rather than an exception to cellular biology in general.​(44)  
Future studies will need to explore the protein responses in more depth and in different               
species to further delineate astrocytic behavior under α7nAChR stimulation, especially the           
peculiarly opposite effect of endotoxin memory in astrocytes and microglia on IL-1β secretion.  
Microglia - astrocyte ensemble interactions need to be studied to bridge the            
methodological gap between ​in vitro experimental design and the ​in situ physiology. This can be               
done in co-cultures, feasible in ovine species, for example.​(14) Recent study in mice highlighted              
the importance of microglia - astrocyte interactions for understanding the polarization dynamics            
of astrocytes.​(45) 
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In an adult rodent model, cholinergic signalling reduced stress responsiveness via CRH          
receptor 1 with positive behavioural changes.​(46) We identified POMC as up regulated under             
α7nAChR stimulation. Considering that CRH is an upstream regulator of POMC, another            
question for future studies is whether we can implicate a direct interaction with the CRH receptor                
1 in the developing brain. 
We found that within its interaction network, GLT-1 was upregulated in microglia and             
astrocytes regardless of cholinergic manipulation, while the up-regulation of JAK1/2 was unique            
to astrocytes. This is in line with studies showing brain region specific overexpression of              
vGluT-1 (SLC17A7) both due to endotoxin stress and due to PS and puts the LPS exposure in                 
the context of a more general brain stress exposure paradigm presenting with shared response              
patterns of neuroinflammation and metabolic adaptations in astrocytes.​(13,47,48) PS has long           
lasting consequences on α7nACh-ergic signaling in frontal cortex and hippocampus reducing           
the expression of α7nAChR protein expression in the brain of adult rats.​(47) 
It is plausible to conclude that low grade neuroinflammation results in changes similar to              
those induced by PS with regard to reprogramming astrocytes to a higher glutamate uptake. As               
shown elsewhere ​(49)​, PS and exposure to endotoxin may act synergistically to exacerbate the              
impairment of neuron-glial glutamatergic interaction. For endotoxin exposure, this process is not            
subject to cholinergic modulation. Whether or not PS effects alone on astrocytes glutamate             
uptake can be ameliorated or reversed by α7nAChR agonism remains to be investigated. 
The phylogenetically conserved interaction between neuroinflammation and chronic        
stress has been the subject of multiple studies ​(24)​, yet we are only beginning to unravel the                 
complex web of interactions, across developmental stages, organs, cell types and           
species-specific differences, which connect these two phenomena. While the role of microglia in             
this context has been appreciated, the response of astrocytes we report here and their behavior               
on protein level under second hit scenario are novel observations warranting further studies in              
different species. 
In summary, we show that genes involved in stress memory of the offspring are also               
impacted by LPS stress, this impact is further altered by a second hit (memory) and that such                
memory of LPS stress is amenable to cholinergic treatment via α7nAChR. It remains to be              
validated in future studies whether, when and which stimulation of the α7nAChR is favourable. 
 
 
 
 
  
13 
AUTHOR CONTRIBUTIONS 
 
MCa, PB, GF, AD, and MGF are responsible for the conception and design.  
MCa, MCo, HLL, MW, LDD, PB, GF, AD and MGF acquired data.  
MCo, MCa, HLL, MW, JWM, MD, TKB, JS and MGF did the analysis and interpretation of data.  
MCo, MCa, JWM, TKB and MGF drafted the manuscript.  
MCo, MCa, MW, JWM, JS, MCA, TKB and MGF are responsible for revising it for intellectual                
content.  
MCo, MCa, HLL, MW, LDD, JWM, PB, GF, AD, JS, MCA, TKB, MD and MGF gave final                 
approval of the completed manuscript. 
 
Funding​: Supported by grants from the Canadian Institute of Health Research (CIHR) (MGF);             
Fonds de la recherche en santé du Québec (FRSQ) (MGF) and Molly Towell Perinatal              
Research Foundation (MGF); QTNPR (by CIHR) (LDD). Supported in part by Illumina Inc. 
 
ACKNOWLEDGEMENTS 
The authors thank Dr. Jack Antel lab, especially Manon Blain, and Dr. Craig Moore for               
invaluable assistance with the cell culture protocol, St-Hyacinthe CHUV team for technical            
assistance and Jan Hamanishi for graphical design. We also thank Dr. Michael Dorschner lab              
for skilful assistance with RNA samples pipeline on the Illumina platform and Lu Wang for               
assistance in RNAseq bioinformatics pipeline. 
  
14 
Figure legends 
 
Figure 1. Experimental design of modulating glial α7nAChR signaling in a double-hit fetal             
sheep model. ​In vivo, in vitro and RNAseq experiments are illustrated. ​In vivo study includes               
Control (saline) or LPS-exposed sheep fetuses. LPS was administered intravenously to the            
instrumented fetus at 400 ng/fetus/day for two consecutive days 24 hours apart, so called first               
hit, inducing fetal inflammatory response with rising IL-6, but without cardiovascular component.            
For the ​in vitro study, cultured cells (microglia or astrocytes) were derived from an ​in vivo                
Control animal, named Naïve, or from an ​in vivo LPS-exposed animal, named second hit (SH).               
There weare 8 experimental groups: naïve Control (NC, vehicle ​in vivo​, vehicle ​in vitro ​), naïve               
LPS (NL, sham in reference to α7nAChR manipulation), naïve exposed to α-Bungarotoxin (NB,             
i.e., α7nAChR inhibition, preincubated followed by LPS exposure), naïve exposed to           
AR-R17779 (NA, i.e., α7nAChR stimulation, preincubated followed by LPS exposure), and each            
respective second-hit groups (SH, LPS ​in vivo ​). Reproduced with permission.​(16)  
 
Figure 2. ​LEFT. IL-1β secretion in ovine primary astrocyte cultures in response to six hours               
LPS exposure without or with pre-incubation with α7nAChR antagonist (B100) or agonist (A10)             
for one hour. Single hit, ​in vitro ​only LPS exposure; second hit, ​in vivo ​systemic and subsequent                 
in vitro ​LPS exposure four to five weeks later. Y axis shows fold changes in IL-1β in relation to                   
baseline secretion levels on log scale. Generalized estimating equations (GEE) modeling results            
are presented in text and no significance marks are provided in the figure. Briefly, we found                
significant main term effects (p=0.019) “treatment” (LPS and α7nAChR drug) as well as main              
term “hit” (p=0.010), ​i.e.​, the contribution of ​in vivo LPS exposure, the second hit effect on the                 
IL-1β secretion profile. Results are provided as median {25-75} percentiles. ​RIGHT​. Identical            
experimental results from microglia studies are presented for comparison. The main terms “hit”             
and “treatment” were not significant (p=0.716 and p=0.666, respectively), but their interaction            
was significant (p=0.026, cf. Fig. 1 in ​(3)​ where the original results have been published.  
 
Figure 3. ​Static 3D plot of the astrocyte RNA-Seq data with single and double-hit LPS               
treatment. The angle of the plot was chosen to give the best viewpoint to show differences                
between the sample types. Note that controls and ​α​7nAChR agonistically pre-treated astrocytes            
cluster together and separately from those exposed to LPS w/o or with antagonistic ​α​7nAChR              
pre-treatment. ​Note here that there are three of the LPS_100_1_hit samples in the plot shown in                
Fig. 3; it just so happens that the third sample is obscured by the uppermost LPS+B100_1_hit                
sample. 
 
Figure 4. ​TOP. PCA plot of microglia and astrocyte samples. Here we can see that astrocytes                
and microglia separate on the first principal component, and the second principal component             
captures the LPS treatment differences. The third principal component captures some           
intra-treatment variability for the microglia samples, particularly for one of the LPS treated             
microglia samples. ​BOTTOM. PCA plot of microglia and astrocyte samples, showing just the             
first two principal components. The largest differences appear to be between the cell types.   
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Table 1. Sample inventory for RNAseq study in astrocytes samples. 
Biological replicates  Serial# Sample Treatment LPS hit number 
Naïve R1 1 4414T1 Ctrl 0 
 
2 4414T1 LPS100 1 
 
3 4414T1 LPS100+B100 1 
 
4 4414T1 LPS100+A10 1 
Naïve R2 5 4414T2 Ctrl 0 
 
6 4414T2 LPS100 1 
 
7 4414T2 LPS100+B100 1 
 
8 4414T2 LPS100+A10 1 
Naïve R3 9 4502P Ctrl 0 
 
10 4502P LPS100 1 
 
11 4502P LPS100+B100 1 
 
12 4502P LPS100+A10 1 
Second hit R1 13 711P Ctrl 1 
 
14 711P LPS100 2 
 
15 711P LPS100+B100 2 
Four replicates were used for RNAseq, with one control and three treatment groups (Ctrl, LPS100, LPS100+A10, LPS100+B100) per replicate. 
There were 3 replicates of naïve, one replicate of second-hit, with one treatment missing in this second-hit replicate (second-hit + Agonist), fifteen 
samples in total were assessed with RNAseq in this study. The instrumented fetuses were designated as primary fetus, identified as animal ID+P 
(stands for primary), whereas animal ID+T stands for non-instrumented twins. 
  
 2 
Table 2. Astrocytes IL-1β secretion expressed as absolute values* in pg/ml (median and 25-75%).  
 
LPS exposure Ctrl LPS B100 A10 
Single hit 1 (1,25) 429 (358,1034) 336 (285,928) 750 (439,1495) 
Second hit 1 (1,1) 16 (15,16) 20 (17, 22) 99 (95, 103) 
* Values set to 1 where no signal was detected by the cytokine assay to compute fold-changes for Fig. 2. 
   
 3 
Table 3. Differentially expressed genes from the fetal sheep astrocytes whole transcriptome analysis: naïve and second hit astrocytes after 
modulation of α7nAChR signaling. Differential analysis of count data was done with the Bioconductor limma package. Differentially expressed 
genes were selected, based on a 1.5-fold change and an FDR < 0.05. Up regulation and down regulation represent positive and negative log2 fold 
changes, respectively. For details on “raw gene” level, see our GitHub repository or directly here. Bold font highlights pathways common with microglia. 
Orange: positive z-score; blue: negative z-score. For further details as raw data and visualized activity patterns see GitHub. 
 
Comparison # genes Top 10 signaling pathways  
 
-log(p-
value) 
Single hit: LPS100 vs Control 1835 
NF-κB Signaling 
Role of Pattern Recognition Receptors in Recognition of Bacteria & Viruses 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis 
Dendritic Cell Maturation 
Neuroinflammation Signaling Pathway 
Role of IL-17A in Arthritis 
Activation of IRF by Cytosolic Pattern Recognition Receptors 
Death Receptor Signaling 
Th1 and Th2 Activation Pathway 
TREM1 Signaling 
 
 
15.8 
14 
 
13.7 
13 
12.8 
12.2 
11.6 
11.3 
10.7 
10.5 
 
Single hit: LPS100+A10 vs Control 1725 
 
NF-κB Signaling 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 
 
14.7 
13.7 
 
13.1 
 4 
Granulocyte Adhesion and Diapedesis 
Role of Pattern Recognition Receptors in Recognition of Bacteria and 
Viruses 
Hepatic Cholestasis 
Toll-like Receptor Signaling 
Axonal Guidance Signaling 
IL-10 Signaling 
Neuroinflammation Signaling Pathway 
 
12.7 
 
12.5 
12.5 
11.7 
11.5 
11.1 
10.7 
 
Single hit: LPS100+B100 vs Control 1744 
 
NF-κB Signaling 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis 
Dendritic Cell Maturation 
Neuroinflammation Signaling Pathway 
Role of Pattern Recognition Receptors in Recognition of Bacteria & Viruses 
TREM1 Signaling 
Role of IL-17A in Arthritis 
T Cell Exhaustion Signaling Pathway 
Toll-like Receptor Signaling 
PI3K Signaling in B Lymphocytes 
 
 
16.8 
16 
15.9 
15 
14.8 
12.8 
12.7 
11.9 
11.8 
11.6 
 
Single hit: LPS100+A10 vs LPS100 273 
 
Granulocyte Adhesion and Diapedesis 
Pathogenesis of Multiple Sclerosis 
Agranulocyte Adhesion and Diapedesis 
 
6.23 
5.81 
5.12 
 5 
Th1 and Th2 Activation Pathway 
Th2 Pathway 
LPS/IL-1 Mediated Inhibition of RXR Function 
NF-κB Signaling 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 
Inhibition of Angiogenesis by TSP1 
STAT3 Pathway 
 
4.45 
4.4 
3.81 
3.71 
3.63 
3.33 
3.25 
 
Single hit: LPS100+B100 vs 
LPS100 0 
  
Single hit: 
LPS100+A10 vs LPS100+B100 292 
 
Granulocyte Adhesion and Diapedesis 
Agranulocyte Adhesion and Diapedesis 
LPS/IL-1 Mediated Inhibition of RXR Function 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 
NF-κB Signaling 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 
Pathogenesis of Multiple Sclerosis 
STAT3 Pathway 
p53 Signaling 
Sirtuin Signaling Pathway 
 
 
5.25 
4.99 
4.38 
4.35 
4.33 
4.18 
3.97 
3.94 
3.57 
3.36 
 
LPS100: single hit vs second hit 3761 
 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 
Leukocyte Extravasation Signaling 
 
10.7 
7.69 
6.82 
 6 
Signaling by Rho Family GTPases 
Iron homeostasis signaling pathway 
LXR/RXR Activation 
Epithelial Adherens Junction Signaling 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 
Axonal Guidance Signaling 
Tec Kinase Signaling 
 
6.16 
6.02 
5.36 
4.99 
4.96 
4.91 
4.82 
 
LPS100+A10: single hit vs second 
hit 3307 
 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 
Leukocyte Extravasation Signaling 
Neuroinflammation Signaling Pathway 
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 
Axonal Guidance Signaling 
Phagosome Formation 
Role of Pattern Recognition Receptors in Recognition of Bacteria and 
Viruses 
Agranulocyte Adhesion and Diapedesis 
GP6 Signaling Pathway 
Granulocyte Adhesion and Diapedesis 
 
 
13 
8.79 
7.18 
6.99 
6.93 
6.85 
6.67 
6.24 
6.1 
5.92 
 
LPS100+B100: single hit vs second 
hit 3860 
 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 
Leukocyte Extravasation Signaling 
Epithelial Adherens Junction Signaling 
 
8.89 
 
8.03 
7.26 
 7 
Iron homeostasis signaling pathway 
Signaling by Rho Family GTPases 
Axonal Guidance Signaling 
Endothelin-1 Signaling 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis 
Phagosome Formation 
 
5.94 
5.78 
5.51 
5.18 
5.04 
5.01 
4.99 
 
Significant genes in astrocytes cultures at an FDR < 0.05 and a 1.5-fold change sorted on log(p-value).  
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Table 4. Differentially expressed genes from the fetal sheep microglia whole transcriptomes analysis. Differential analysis of count data was 
done with the Bioconductor limma package. Differentially expressed genes were selected, based on a 1.5-fold change and an FDR < 0.05. Up 
regulation and down regulation represent positive and negative log2 fold changes, respectively. For details on “raw gene” level, see our GitHub 
repository or directly here. Bold font highlights signaling pathways common with astrocytes. Orange: positive z-score; blue: negative z-score. For 
further details as raw data and visualized activity patterns see GitHub. 
 
Comparison # genes Top 10 signaling pathways -log(p-value) 
LPS100 vs Control 1779 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 
Dendritic Cell Maturation 
iNOS Signaling 
Role of IL-17A in Arthritis 
IL-10 Signaling 
Role of Tissue Factor in Cancer 
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 
Neuroinflammation Signaling Pathway 
Toll-like Receptor Signaling 
CD40 Signaling 
 
16.7 
12.9 
12.6 
12.5 
11.8 
11.6 
11.1 
10.9 
10.7 
10 
 
LPS100+A10 vs Control 4721 
Molecular Mechanisms of Cancer 
Colorectal Cancer Metastasis Signaling 
Toll-like Receptor Signaling 
NF-κB Signaling 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 
PI3K Signaling in B Lymphocytes 
Role of Tissue Factor in Cancer 
B Cell Receptor Signaling 
14.1 
11.2 
11 
10.6 
10.4 
10.4 
10.3 
9.83 
 9 
TREM1 Signaling 
Protein Kinase A Signaling 
 
7.83 
7.81 
 
LPS100+B100 vs Control 4049 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 
PI3K Signaling in B Lymphocytes 
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 
Molecular Mechanisms of Cancer 
Activation of IRF by Cytosolic Pattern Recognition Receptors 
IL-10 Signaling 
B Cell Receptor Signaling 
iNOS Signaling 
Role of Tissue Factor in Cancer 
Toll-like Receptor Signaling 
 
13.6 
11.4 
10.2 
10.2 
10.2 
9.63 
9.55 
9.21 
9.06 
8.93 
 
LPS100+A10 vs LPS100 8   
LPS100+B100 vs LPS100 0   
LPS100+A10 vs 
LPS100+B100 1132 
T Cell Exhaustion Signaling Pathway 
Dendritic Cell Maturation 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 
Th17 Activation Pathway 
Leukocyte Extravasation Signaling 
Superpathway of Cholesterol Biosynthesis 
IL-10 Signaling 
Role of Tissue Factor in Cancer 
5.46 
5.43 
5.42 
 
5.22 
5.16 
4.81 
4.8 
4.49 
4.31 
 10 
Th1 and Th2 Activation Pathway 
 
4.26 
 
Significant genes in microglia cultures at an FDR < 0.05 and a 1.5-fold change sorted on log(p-value). 
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Table 5. Genes unique to LPS, agonistic and antagonistic stimulation of α7nAChR in single hit astrocytes cultures. 
 
 
 
Top 10 signaling pathways -log(p-value) 
Genes unique to LPS100 Ephrin A Signaling 3.21 
 
P2Y Purigenic Receptor Signaling Pathway 2.72 
 
Role of p14/p19ARF in Tumor Suppression 2.55 
 
Thiamin Salvage III 2.2 
 
Melanoma Signaling 2.14 
 
Lymphotoxin β Receptor Signaling 2.03 
 
CCR3 Signaling in Eosinophils 1.96 
 
CD40 Signaling 1.84 
Genes unique to A10 Germ Cell-Sertoli Cell Junction Signaling 9.13 
 
Integrin Signaling 7.4 
 
Actin Cytoskeleton Signaling 5.84 
 
Leukocyte Extravasation Signaling 5.81 
 
Sertoli Cell-Sertoli Cell Junction Signaling 5.58 
 
GDP-glucose Biosynthesis 5.49 
 
Glucose and Glucose-1-phosphate Degradation 5.24 
 
Phagosome Formation 4.84 
 
Signaling by Rho Family GTPases 4.71 
 
HGF Signaling 4.6 
Genes unique to B100 Apelin Cardiomyocyte Signaling Pathway 5.54 
 12 
  Adrenomedullin signaling pathway 4.09 
 
Dendritic Cell Maturation 3.23 
 
Endothelin-1 Signaling 3.2 
 
UVA-Induced MAPK Signaling 3.2 
 
Renin-Angiotensin Signaling 2.97 
 
Role of NFAT in Cardiac Hypertrophy 2.95 
 
Phagosome Formation 2.95 
 
GP6 Signaling Pathway 2.91 
 
Wnt/Ca+ pathway 2.89 
EXPERIMENTAL DESIGN
Cortes et al. J Neurosci Methods. 2017; 276: 23–32.
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